Literature DB >> 11919426

Cutaneous mastocytosis -- clinical heterogeneity.

Karin Hartmann1, Beate M Henz.   

Abstract

Cutaneous mastocytosis (CM) encompasses several distinct patterns of disease which can be distinguished by the type of skin lesions, age of onset, familial occurrence, noncutaneous involvement, associated c-kit mutations, and prognosis. A clear distinction of the type of CM in individual patients has important implications regarding patient management and prognosis. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh：

Year:  2002        PMID： 11919426     DOI： 10.1159/000048187

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN： 1018-2438            Impact factor:   2.749


  9 in total

1.  Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT.

Authors:  Peter Valent; Sabine Cerny-Reiterer; Gregor Hoermann; Wolfgang R Sperr; Leonhard Müllauer; Christine Mannhalter; Hubert Pehamberger
Journal:  Am J Blood Res       Date:  2014-12-15

2.  Mast cell distribution in normal adult skin.

Authors:  A S Janssens; R Heide; J C den Hollander; P G M Mulder; B Tank; A P Oranje
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

Review 3.  Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis?

Authors:  A Matito; M Carter
Journal:  Curr Allergy Asthma Rep       Date:  2015-05       Impact factor: 4.806

4.  Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology.

Authors:  Peter Valent
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

Review 5.  Contemporary challenges in mastocytosis.

Authors:  H David Pettigrew; Suzanne S Teuber; James S Kong; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

6.  CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.

Authors:  Niklas Mueller; Daniel Wicklein; Gregor Eisenwort; Mohamad Jawhar; Daniela Berger; Gabriele Stefanzl; Georg Greiner; Alexandra Boehm; Christoph Kornauth; Leonhard Muellauer; Susanne Sehner; Gregor Hoermann; Wolfgang R Sperr; Philipp B Staber; Ulrich Jaeger; Johannes Zuber; Michel Arock; Udo Schumacher; Andreas Reiter; Peter Valent
Journal:  Blood       Date:  2018-07-17       Impact factor: 22.113

Review 7.  European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives.

Authors:  Peter Valent; Michel Arock; Patrizia Bonadonna; Knut Brockow; Sigurd Broesby-Olsen; Luis Escribano; Karoline V Gleixner; Clive Grattan; Emir Hadzijusufovic; Hans Hägglund; Olivier Hermine; Hans-Peter Horny; Hanneke C Kluin-Nelemans; Marcus Maurer; Marek Niedoszytko; Boguslaw Nedoszytko; Gunnar Nilsson; Hanneke N G Oude-Elberink; Alberto Orfao; Deepti Radia; Andreas Reiter; Frank Siebenhaar; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Jaap J VanDoormaal; Judit Várkonyi; Selim Yavuz; Karin Hartmann
Journal:  Wien Klin Wochenschr       Date:  2012-11-20       Impact factor: 1.704

8.  Mastocytosis presenting as cardiac emergency.

Authors:  Erminia Ridolo; Massimo Triggiani; Marcello Montagni; Elisa Olivieri; Andrea Ticinesi; Antonio Nouvenne; Diomira Magliacane; Gennaro de Crescenzo; Tiziana Meschi
Journal:  Intern Emerg Med       Date:  2013-10-18       Impact factor: 3.397

9.  Mastocytosis in children and adults: clinical disease heterogeneity.

Authors:  Magdalena Lange; Bogusław Nedoszytko; Aleksandra Górska; Anton Zawrocki; Michał Sobjanek; Dariusz Kozlowski
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.